A prosztataspecifikus antigén-vizsgacalat elso évtizede klinikánkon (1994-2004)

Translated title of the contribution: Investigation of prostate specific antigen in the first decade of its use, in our clinic (1994-2004)

Gergely Bánfi, Tibor Glasz, Eszter Székely, I. Romics

Research output: Contribution to journalArticle

Abstract

Introduction and aims: Prostate cancer is the most common malignant tumor in male; its diagnostic algorithm and therapy were investigated. The goal of the study was to compare the data from the first year of clinical use of prostate specific antigen (1994) and the data of 2004. Results: During the first decade, the number of prostate biopsies has increased 4.5-fold times. In 1994, 36.2%, while in 2004, 47.5% of the biopsies demonstrated cancer. The average age of the patients, who underwent biopsy, decreased from 69.7 to 62.3 years; however, the average age of patients who suffered from prostate cancer reamined constant (70.8 vs. 71.3 years old). Conclusion: In 2004, along with the earlier used PSA level, the free-PSA and PSA-density was also involved in the diagnostic algorithm. The prostate biopsy is guided by a transrectal US, in contrast to the earlier used blind or transperineal method. Consequently, the effectiveness of the prostate biopsy has improved, but the earlier diagnosis and identification are not assured. The Gleason score of the diagnosed prostate cancer was lower; therefore, more patients were selected for curative surgery. The increased average PSA level reflected a higher number of patients at an advanced stage, which could only be treated palliatively.

Original languageHungarian
Pages (from-to)121-124
Number of pages4
JournalOrvosi Hetilap
Volume148
Issue number3
DOIs
Publication statusPublished - Jan 21 2007

Fingerprint

Prostate-Specific Antigen
Biopsy
Prostate
Prostatic Neoplasms
Neoplasm Grading
Early Diagnosis
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A prosztataspecifikus antigén-vizsgacalat elso évtizede klinikánkon (1994-2004). / Bánfi, Gergely; Glasz, Tibor; Székely, Eszter; Romics, I.

In: Orvosi Hetilap, Vol. 148, No. 3, 21.01.2007, p. 121-124.

Research output: Contribution to journalArticle

Bánfi, Gergely ; Glasz, Tibor ; Székely, Eszter ; Romics, I. / A prosztataspecifikus antigén-vizsgacalat elso évtizede klinikánkon (1994-2004). In: Orvosi Hetilap. 2007 ; Vol. 148, No. 3. pp. 121-124.
@article{c98846911c5b456a89be7350b49d37af,
title = "A prosztataspecifikus antig{\'e}n-vizsgacalat elso {\'e}vtizede klinik{\'a}nkon (1994-2004)",
abstract = "Introduction and aims: Prostate cancer is the most common malignant tumor in male; its diagnostic algorithm and therapy were investigated. The goal of the study was to compare the data from the first year of clinical use of prostate specific antigen (1994) and the data of 2004. Results: During the first decade, the number of prostate biopsies has increased 4.5-fold times. In 1994, 36.2{\%}, while in 2004, 47.5{\%} of the biopsies demonstrated cancer. The average age of the patients, who underwent biopsy, decreased from 69.7 to 62.3 years; however, the average age of patients who suffered from prostate cancer reamined constant (70.8 vs. 71.3 years old). Conclusion: In 2004, along with the earlier used PSA level, the free-PSA and PSA-density was also involved in the diagnostic algorithm. The prostate biopsy is guided by a transrectal US, in contrast to the earlier used blind or transperineal method. Consequently, the effectiveness of the prostate biopsy has improved, but the earlier diagnosis and identification are not assured. The Gleason score of the diagnosed prostate cancer was lower; therefore, more patients were selected for curative surgery. The increased average PSA level reflected a higher number of patients at an advanced stage, which could only be treated palliatively.",
keywords = "Biopsy, Prostate cancer, PSA",
author = "Gergely B{\'a}nfi and Tibor Glasz and Eszter Sz{\'e}kely and I. Romics",
year = "2007",
month = "1",
day = "21",
doi = "10.1556/OH.2007.27810",
language = "Hungarian",
volume = "148",
pages = "121--124",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - A prosztataspecifikus antigén-vizsgacalat elso évtizede klinikánkon (1994-2004)

AU - Bánfi, Gergely

AU - Glasz, Tibor

AU - Székely, Eszter

AU - Romics, I.

PY - 2007/1/21

Y1 - 2007/1/21

N2 - Introduction and aims: Prostate cancer is the most common malignant tumor in male; its diagnostic algorithm and therapy were investigated. The goal of the study was to compare the data from the first year of clinical use of prostate specific antigen (1994) and the data of 2004. Results: During the first decade, the number of prostate biopsies has increased 4.5-fold times. In 1994, 36.2%, while in 2004, 47.5% of the biopsies demonstrated cancer. The average age of the patients, who underwent biopsy, decreased from 69.7 to 62.3 years; however, the average age of patients who suffered from prostate cancer reamined constant (70.8 vs. 71.3 years old). Conclusion: In 2004, along with the earlier used PSA level, the free-PSA and PSA-density was also involved in the diagnostic algorithm. The prostate biopsy is guided by a transrectal US, in contrast to the earlier used blind or transperineal method. Consequently, the effectiveness of the prostate biopsy has improved, but the earlier diagnosis and identification are not assured. The Gleason score of the diagnosed prostate cancer was lower; therefore, more patients were selected for curative surgery. The increased average PSA level reflected a higher number of patients at an advanced stage, which could only be treated palliatively.

AB - Introduction and aims: Prostate cancer is the most common malignant tumor in male; its diagnostic algorithm and therapy were investigated. The goal of the study was to compare the data from the first year of clinical use of prostate specific antigen (1994) and the data of 2004. Results: During the first decade, the number of prostate biopsies has increased 4.5-fold times. In 1994, 36.2%, while in 2004, 47.5% of the biopsies demonstrated cancer. The average age of the patients, who underwent biopsy, decreased from 69.7 to 62.3 years; however, the average age of patients who suffered from prostate cancer reamined constant (70.8 vs. 71.3 years old). Conclusion: In 2004, along with the earlier used PSA level, the free-PSA and PSA-density was also involved in the diagnostic algorithm. The prostate biopsy is guided by a transrectal US, in contrast to the earlier used blind or transperineal method. Consequently, the effectiveness of the prostate biopsy has improved, but the earlier diagnosis and identification are not assured. The Gleason score of the diagnosed prostate cancer was lower; therefore, more patients were selected for curative surgery. The increased average PSA level reflected a higher number of patients at an advanced stage, which could only be treated palliatively.

KW - Biopsy

KW - Prostate cancer

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=34248549828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248549828&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.27810

DO - 10.1556/OH.2007.27810

M3 - Article

C2 - 17289616

AN - SCOPUS:34248549828

VL - 148

SP - 121

EP - 124

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 3

ER -